GPT caught in a bind
Securityholders left GPT’s annual meeting in May thinking everything was hunky dory. Nine weeks later the group is in turmoil.
Plot thickens for Seven and CMH
Rumour has it that Seven has taken a stake in CMH. If so, it highlights our concerns about management.
ASX faces the AXE
Business quality gets less coverage than price, but it’s just as important in the value equation. Here we put ASX to the test.
Fantastic's careful juggling act
With a downturn underway, it might not seem like an ideal time for a furniture retailer to expand – or for investors to buy its shares. But going against the crowd often pays dividends in the long run.
First cut the deepest for Mortgage Choice
All the major banks have now cut their mortgage broking commissions, but the cuts have generally been smaller than Westpac’s trailblazing reductions.
BBI EPS - silly name for a speculative punt
This income security is an orphan, the by-product of a doomed marriage and an eyesore to most potential adopters. That’s exactly why we’re taking a closer look.
Corporate action at Corporate Express?
We don’t go chasing takeover rumours. But we like this stock anyway, so there’s no harm in the fact that others seem to as well.
Australian Wealth mauled by the bear
AWM’s share price, buoyant before its latest acquisition, has lately resumed its swan dive. That’s enough for us to upgrade again, despite a few misgivings about the acquisition.
Packer and Stokes find another Bondy
After offloading part of their media empires to private equity, Kerry Stokes and James Packer have cash to burn – which is just what we’re afraid of.
Cash up for classy Cochlear
As one of Australia’s finest companies, Cochlear’s shares are never in the bargain basement. But, like its famous ear implants, you get what you pay for.
Flame still burns at Harvey Norman
JB Hi-Fi seems to be stealing a march on the technology-loving youth market, but Harvey Norman has prospered before in tough times.
Don't spoil our Roc Oil!
We’ve supported this company for many years, but we’re terribly disappointed by the large, dilutive acquisition the board wants to make.
Call 1300 880 160
Start a chat
Schedule a call
